MP0317 + Gemcitabine + Cisplatine + Durvalumab + Gemcitabine + Cisplatin + Durvalumab
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Biliary Tract Carcinoma
Conditions
Advanced Biliary Tract Carcinoma
Trial Timeline
Dec 22, 2025 → Nov 1, 2029
NCT ID
NCT07036380About MP0317 + Gemcitabine + Cisplatine + Durvalumab + Gemcitabine + Cisplatin + Durvalumab
MP0317 + Gemcitabine + Cisplatine + Durvalumab + Gemcitabine + Cisplatin + Durvalumab is a phase 2 stage product being developed by Molecular Partners for Advanced Biliary Tract Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07036380. Target conditions include Advanced Biliary Tract Carcinoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Biliary Tract Carcinoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07036380 | Phase 2 | Recruiting |
Competing Products
20 competing products in Advanced Biliary Tract Carcinoma